October 31, 2013-The Economic Times: Patent office rejects BDR Pharma's compulsory licensing applicationAugust 6, 2013: Kractivism: Press Release- Campaign for Affordable Trastuzumab (links to kractivist.org) August 5, 2013 - Bio World: China Revokes Viread Patent; Pricing Was at Issue (links to bioworld.com)
May 30, 2013- The Jakarta Globe: Future Hepatitis C Blockbusters May Spawn Compulsory Generics (links to thejakartaglobe.com)March 18, 2013- ACTION! Essential Inventions issues request for non-voluntary authorization to use patents under Article 14 of Greece patent law (links to essentialinventions.org)
March 17, 2013-Financial Times: Athens urged to import generic drugs (links to ft.com)December, 2012- Secondary Patenting: A Threat to Affordable Generic Patenting by I-MAK
November 2, 2012- Nature: NIH asked to grant open license on HIV drug (links to blogs.nature.com)
October 25, 2012-ACTION! Knowledge Ecology International: Four NGOs ask NIH to grant open licenses to ritonavir patents under Bayh-Dole March-in provisions (links to keionline.org)
October 22, 2012-The Star (Malaysia): Measure to make drugs affordable (links to thestar.com.my)
October 12, 2012-Reuters: Indonesia acts to over-ride patents on HIV drugs (links to uk.reuters.com)
October 11, 2012-ACTION! The Guardian: Indonesia in bold move to obtain cheap drugs for HIV (links to guardian.co.uk)
Link to Indonesia action page
For more information, contact us at firstname.lastname@example.org
ACCESS VICTORIES AND THE KALETRA CAMPAIGN
On November 10, public health groups in a dozen countries launched a global campaign to challenge Abbott Laboratories’ monopolistic hold on Kaletra (lopinavir+ritonavir), a critical HIV/AIDS medicine. The goal is to spur competition by generic drugmakers and thereby lower the medicine’s price, as well as to free up its components for new and improved combination treatments.
The new campaign comprises an unprecedented global effort to fight Big Pharma’s political power and improve access to lifesaving medicines
Back to Public Citizen Global Access to Medicines Home Page
Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.
Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.
Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.
You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.